Activity

Filter

Cancel
Date Panel Item Activity
7 actions
BabyScreen+ newborn screening v1.114 TPK1 Tommy Li Added phenotypes Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type) MIM#614458 for gene: TPK1
BabyScreen+ newborn screening v0.1986 TPK1 Zornitza Stark Marked gene: TPK1 as ready
BabyScreen+ newborn screening v0.1986 TPK1 Zornitza Stark Gene: tpk1 has been classified as Green List (High Evidence).
BabyScreen+ newborn screening v0.1986 TPK1 Zornitza Stark Classified gene: TPK1 as Green List (high evidence)
BabyScreen+ newborn screening v0.1986 TPK1 Zornitza Stark Gene: tpk1 has been classified as Green List (High Evidence).
BabyScreen+ newborn screening v0.1985 TPK1 Zornitza Stark Tag treatable tag was added to gene: TPK1.
Tag metabolic tag was added to gene: TPK1.
BabyScreen+ newborn screening v0.1982 TPK1 Lilian Downie gene: TPK1 was added
gene: TPK1 was added to Baby Screen+ newborn screening. Sources: Expert list
Mode of inheritance for gene: TPK1 was set to BIALLELIC, autosomal or pseudoautosomal
Publications for gene: TPK1 were set to PMID: 33086386, 32679198, 22152682, PMID: 33231275
Phenotypes for gene: TPK1 were set to Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type) MIM#614458
Review for gene: TPK1 was set to GREEN
Added comment: Strong gene disease association
Variable age of onset but always under 5years

Thiamine metabolism dysfunction syndrome-5 (THMD5) is an autosomal recessive metabolic disorder due to an inborn error of thiamine metabolism. The phenotype is highly variable, but in general, affected individuals have onset in early childhood of acute encephalopathic episodes associated with increased serum and CSF lactate. These episodes result in progressive neurologic dysfunction manifest as gait disturbances, ataxia, dystonia, and spasticity, which in some cases may result in loss of ability to walk. Cognitive function is usually preserved, although mildly delayed development has been reported. These episodes are usually associated with infection and metabolic decompensation. Some patients may have recovery of some neurologic deficits (Mayr et al., 2011).

Biotin and thiamine therapy - newer evidence (2021) suggests early thiamine therapy may prevent any neurologic deficits.
Sources: Expert list